AERAS  [to 28 Jul 2018]
No new digest content identified.
BMGF – Gates Foundation  [to 28 Jul 2018]
No new digest content identified.

Bill & Melinda Gates Medical Research Institute    [to 28 Jul 2018]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X   [to 28 Jul 2018]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations  [to 28 Jul 2018]
No new digest content identified.

EDCTP    [to 28 Jul 2018]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center    [to 28 Jul 2018]
No new digest content identified.

European Medicines Agency  [to 28 Jul 2018]
[Website offline for maintenance at inquiry]
European Vaccine Initiative  [to 28 Jul 2018]
No new digest content identified.
FDA [to 28 Jul 2018]
No new digest content identified.

Fondation Merieux  [to 28 Jul 2018]
Mérieux Foundation event
Global challenges in vaccine acceptance science and programs
September 24 – 26, 2018 – Les Pensieres Center for Global Health, Veyrier du Lac (France)

Gavi [to 28 Jul 2018]
26 July 2018
Children in fragile states missing out on lifesaving vaccines
New vaccination figures show millions more children being immunised in world’s poorest countries.
[See Milestones/Perspectives above for more detail]

25 July 2018
Ebola vaccine praised as Congo outbreak declared over
DRC government officially declares end of outbreak following the vaccination of over 3,000 people.
[See Milestones/Perspectives above for more detail]
GHIT Fund   [to 28 Jul 2018]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

Global Fund [to 28 Jul 2018];&country=
Global Fund Joins AIDS 2018 to Break Barriers and Build Bridges
25 July 2018
At the International AIDS Conference, the Global Fund to Fight AIDS, Tuberculosis and Malaria joined efforts to accelerate the end of the HIV epidemic, linking civil society, scientific experts and policymakers from all over the world on the conference theme of breaking barriers and building bridges.
Hilleman Laboratories   [to 28 Jul 2018]
No new digest content identified.
Human Vaccines Project   [to 28 Jul 2018]
No new digest content identified.
IAVI  [to 28 Jul 2018]
No new digest content identified.
No new digest content identified.

IVAC  [to 28 Jul 2018]
New Research: Using pneumococcal and rotavirus surveillance in vaccine decision-making: A series of case studies in Bangladesh, Armenia and the Gambia
July 2018
Through a series of country case studies, this paper reviews the successful use of surveillance data for disease caused by pneumococcus and rotavirus in informing national vaccine policy in Bangladesh, Armenia and The Gambia. The case studies delve into ways in which countries are leveraging and building capacity in existing surveillance infrastructure to monitor other diseases of concern in the country.
IVI   [to 28 Jul 2018]
IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience

– Grant from the Bill & Melinda Gates Foundation to allow SK Bioscience Co. Ltd, IVI to accelerate late-stage development of new vaccine necessary to achieve WHO prequalification

The International Vaccine Institute (IVI), an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, has been awarded a US$5 million grant from the Bill & Melinda Gates Foundation to support the development of a Vi-DT typhoid conjugate vaccine in collaboration with its manufacturer, SK Bioscience Co. Ltd..

The grant will support the process development and scale-up activities at SK Bioscience in preparation for a Phase III clinical trial prior to licensure and World Health Organization prequalification of the vaccine. Specifically, the grant will cover the cost of the Chemistry, Manufacturing, and Control (CMC) activities and process-validation batch production for the Phase III clinical trial. The phase I study of SK Vi-DT has already been completed in the Philippines and the vaccine was found to be safe and immunogenic. The phase II study is currently underway in the Philippines.

“This grant will allow SK and IVI to complete all activities critical to low-cost manufacturing and WHO prequalification of the Vi-DT conjugate,” said Dr. Sushant Sahastrabuddhe, Director of IVI’s Typhoid Program. “Through the project, we aim to ensure global supply and therefore access of the vaccine at an affordable price for populations in low and lower-middle income countries.”…

“Typhoid is a poverty-associated infectious disease. Like cholera, it strikes the impoverished and frequently occurs in low-income settings where there is a lack of access to clean water, and where sanitation and hygiene are poor. Infants and young children, in particular, are at risk,” said IVI’s Director General Dr. Jerome Kim. “IVI is proud to have developed a Vi-DT typhoid conjugate vaccine, and we will accelerate our collaboration with SK Bioscience to bring this vaccine to market and help achieve WHO prequalification; which will make it the second manufacturer of a TCV for the public health market.”

JEE Alliance  [to 28 Jul 2018]
No new digest content identified.
MSF/Médecins Sans Frontières  [to 28 Jul 2018]
Selected Press Releases/Statements
Sierra Leone
Winning people’s trust in healthcare
Project Update 27 Jul 2018

MSF opens emergency nutrition programme in N’Djamena
Press Release 27 Jul 2018

DRC 2018 Ebola outbreak
Ministry of Health declares Ebola epidemic over
Project Update 25 Jul 2018
…“Médecins Sans Frontières (MSF) welcomes this announcement and the end of the Ebola epidemic,” says MSF medical director Dr Micaela Serafini.
“Since the beginning of the outbreak, MSF set up its medical response along with national health authorities, providing care, isolation of patients and health promotion activities, in addition to participating in epidemiological surveillance and safe burials in Mbandaka, Bikoro, Itipo and Iboko.
Along with the Ministry of Health and the World Health Organization (WHO), MSF also participated in an investigational vaccination to hold off the spread of the virus. The data is still being analysed, but we are encouraged that this vaccination – as well as the rapid international response and concerted outreach efforts into remote communities – contributed to stemming the spread of this deadly virus. Vaccination provides an additional tool for fighting such epidemics…

Annual Report
International Activity Report 2017
24 Jul 2018

Stopping Senseless Deaths: Overcoming access barriers to affordable, lifesaving diagnostics and treatments for HIV and opportunistic infections
Report 23 Jul 2018
This technical brief analyses access barriers to affordable, lifesaving diagnostics and treatments for HIV and OIs, including adult and paediatric formulations of dolutegravir – a highly effective and tolerable HIV integrase inhibitor that replaces efavirenz in first-line treatment regimens. Updated antiretroviral drug pricing information is also provided.

Pfizer and GSK’s HIV/AIDS division, ViiV, prevents children with HIV from getting needed medicine [dolutegravir]
Press Release 23 Jul 2018

Towards Peer-Led HIV and SRH Services for Sex Workers and Men
Report 23 Jul 2018

Meeting the specific needs of key populations living with HIV
Project Update 23 Jul 2018

NIH  [to 28 Jul 2018]
July 25, 2018
Tickborne diseases are likely to increase, say NIH officials
Bacteria cause most tickborne diseases in the United States.

July 25, 2018
Fauci: HIV remission free of antiretroviral therapy is a feasible goal
NIAID director will give special session lecture at AIDS 2018 Conference.

July 24, 2018
NIH expands program that conducts large-scale clinical trials in real-world settings
Ongoing studies focus on many different diseases, including colon cancer, chronic pain and kidney failure.
The National Institutes of Health’s Health Care Systems (HCS) Research Collaboratory, which involves health care systems in conducting large-scale clinical studies, has announced five new research awards — totaling $4.15 million for a one-year planning phase, with an estimated $30.85 million expected for four subsequent years of study implementation. The HCS Research Collaboratory was developed by the NIH Common Fund in 2012 and is administered by the National Center for Complementary and Integrative Health (NCCIH) and the National Institute on Aging (NIA). The HCS Research Collaboratory is currently supporting nine large-scale clinical trials with health care systems across the United States, and a collaboratory coordinating center at Duke University, Durham, North Carolina. The ongoing trials focus on many different diseases, including colon cancer, chronic pain, kidney failure, hospital-acquired infections, suicide prevention, and multiple chronic medical conditions.
Health care systems, which include health maintenance organizations and other large integrated care settings, see large populations of patients. Through these collaborative research projects, NIH is also able to conduct large-scale and cost-effective clinical research on a variety of diseases within the settings where patients are already receiving their care.
“The collaboratory program pioneered efforts at NIH to conduct large-scale clinical trials within health care systems, and we are excited about expanding this initiative,” said David Shurtleff, Ph.D., NCCIH acting director. “Conducting clinical trials in real-world settings is a critical aspect of the collaboratory program.”
“This kind of trans-NIH collaboration is important as we test interventions on a large scale and in real world clinical care settings,” said Richard J. Hodes, M.D., director of NIA, who oversees the collaboratory with Shurtleff…


PATH  [to 28 Jul 2018]
No new digest content identified.


Sabin Vaccine Institute  [to 28 Jul 2018]
No new digest content identified.
UNAIDS [to 28 Jul 2018]
27 July 2018
Defending the rights of people living with HIV at community level in the Russian Federation

26 July 2018
How HIV treatment numbers are shown to be accurate
26 July 2018
Sustaining the HIV response in Latin America

25 July 2018
Reaching the 10-10-10 will put Europe on track to achieving the SDG targets

24 July 2018
Health leaders from 10 countries in eastern Europe and central Asia reaffirm commitment to scale up the AIDS response

24 July 2018
Global HIV Prevention Coalition implements the HIV Prevention 2020 Road Map


UNICEF  [to 28 Jul 2018]
Selected Press Releases/Reports/Statements
Press release
Rohingya refugee children face onset of deadly monsoon rains

Press release
Nearly 25 per cent of boys aged 15 out of school in the State of Palestine
Adolescent boys out of school due to the low quality of education, lack of relevance to their young lives, physical and emotional violence in schools, and conflict

Press release
Children affected by floods in Laos need urgent support
UNICEF and partners working to save lives and reach the most vulnerable children

Press release
Every three minutes a teenage girl is infected by HIV – UNICEF
Teenage girls bear brunt of a far-from-over HIV/AIDS epidemic

Access to water continues to be jeopardized for millions of children in war-torn Yemen
Statement attributable to Geert Cappelaere, UNICEF Regional Director in the Middle East and North Africa

Press release
DRC Ebola epidemic ends, but ongoing vigilance is essential to keeping children safe from future outbreaks – UNICEF

Vaccine Confidence Project  [to 28 Jul 2018]
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 28 Jul 2018]
Webinar registration open
Registration is now open for the next “Current Issues in Vaccines” webinar. Dr. Offit will speak about the following topics during the event scheduled for Wednesday, Sept. 5, 2018, at noon ET
Wellcome Trust  [to 28 Jul 2018]
News  / Published: 26 July 2018
Wellcome to use Researchfish for reporting research outcomes
From February 2019, Wellcome will ask most Science and Humanities & Social Science grantholders to use the Researchfish platform when reporting research outcomes at the end of their awards.
This will replace our current end-of-grant report, and will capture research outputs such as publications, intellectual property and software tools, and other outcomes such as influence on policy.
The change follows on from our announcement earlier this year about the Wellcome Success Framework, which set out nine ambitions that express what success looks like across all Wellcome’s work.
The data from Researchfish (opens in a new tab) will help us assess progress against these ambitions. It will be used at an aggregate level to gain a deeper understanding of what is being achieved through Wellcome grants and in partnership with others.
We won’t use it to assess the impact of individual grants, or to inform decisions about individual funding applications.
Collecting data in this way will also make it easier for research offices and researchers to record…

News / Published: 24 July 2018
Wellcome’s gender pay gap data for 2018
Today, we’re publishing our gender pay gap statistics which show a 17.4% median gender pay gap on 5 April 2018. This is an improvement on our 2017 gap of 20.8% and slightly better than the 2017 UK average of 18.4%.
The Wistar Institute   [to 28 Jul 2018]
No new digest content identified.


World Organisation for Animal Health (OIE)   [to 28 Jul 2018]
No new digest content identified.

BIO    [to 28 Jul 2018]
No new digest content identified.


DCVMN – Developing Country Vaccine Manufacturers Network  [to 28 Jul 2018]
No new digest content identified.


IFPMA   [to 28 Jul 2018]
No new digest content identified.

PhRMA    [to 28 Jul 2018]
No new digest content identified.